PRMT6 Inhibitors

Protein arginine methyltransferase 6 (PRMT6) is an enzyme involved in the methylation of arginine residues on histones and other proteins, playing a critical role in gene regulation, DNA repair, and RNA processing. Inhibitors of PRMT6 are of significant interest in the field of epigenetics. The PRMT6 inhibitors are primarily characterized by their ability to target the enzyme's S-Adenosylmethionine (SAM) binding site or its substrate-binding domain, thereby disrupting its methyltransferase activity. MS023 and EPZ020411 exemplify this by competitively inhibiting the SAM binding site. GSK3368715 and LLY-283 also function by inhibiting the substrate binding and methyltransferase activity of PRMT6, showcasing a direct mechanism of action.

Furamidine, originally developed as an anti-parasitic agent, has been identified to possess inhibitory effects on PRMT6. SGC707, with its allosteric mode of inhibition, exemplifies a different approach by inducing conformational changes in PRMT6, thereby reducing its enzymatic activity. CMP5 and C21 are selective inhibitors that focus on the PRMT6 active site. DS-437, although having multi-activity against various PRMTs, has shown significant efficacy in inhibiting PRMT6 through similar mechanisms. DC-S239 represents a novel approach in PRMT6 inhibition, specifically designed to target its active site. AMI-1 and Allantoin, although not as potent or specific as other listed compounds, contribute to the diversity of the inhibitors. AMI-1 operates through a less defined mechanism but affects PRMT6's methyltransferase function. Allantoin, more commonly known for its dermatological applications, has been identified to weakly inhibit PRMT6, suggesting potential for further chemical modifications to enhance its efficacy.